Modifiable Variables in Parkinsonism (MVP)
Study Details
Study Description
Brief Summary
We are trying to identify factors associated with improved quality of life and fewer PD symptoms. We are attempting to identify practices, beliefs, and therapies used by individuals who report excellent quality of life, few PD symptoms, and reduced rates of progression. After agreeing to participate, we will ask participants to fill our questionnaires about their experience with PD, their health in general, along with their food intake every six months for five years.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
This is a prospective, observational study designed to describe disease progression, symptom change, quality of life, diet and lifestyle habits among patients with Parkinson's disease (PD). This study will identify and describe those individuals with the highest quality of life and least amount of disease activity, in order to describe medication, diet, and lifestyle patterns associated with a lack of PD disease progression and high quality of life.
Participants will be asked to complete online surveys every six months for five years. The time requirement is about an hour to an hour and a half every six months. Participants do not need to answer questions if they do not feel comfortable answering.
At each six month time point we will send participants an email with the link to the CAM Care in PD survey, a questionnaire about health and wellbeing (completed in REDCap). After participants have completed this survey we will send participants a link to the second survey, about dietary intake (completed on ASA24.gov). Because there is a designated window of time during which surveys must be completed, participants may receive a gentle reminder from us if time is running out.
This study is not designed to provide care. Participants are encouraged to consult with any providers you wish. Participants will not directly benefit from the study, but information gathered during the course of this study may help us begin to assess the longer-term effects of complementary and integrative care on health, disease progression and quality of life in PD patients.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Parkinson's Disease Patients Any individuals who has a diagnosis of Parkinson's disease (PD), parkinsonism, or a parkinson's plus syndrome will be allowed to participate. |
Outcome Measures
Primary Outcome Measures
- CAM Care for PD survey [5 years]
This survey has been developed to identify the complementary and alternative therapies most commonly used by individuals with PD. Results will be reported with descriptive statistics.
- PROMIS: Global Health [5 years]
This outcome measure will be used to assess general health and well-being in the cohort.
- Patient-Reported Outcomes in PD (PRO-PD) [5 years]
This outcome measure is a series of 33 slider bars, developed for this study, to evaluate the individual's perception of symptom severity. The cumulative score for all 33 listed symptoms will be reported as the PRO-PD score.
Secondary Outcome Measures
- Qualitative [5 years]
Participants will be given 'free space' to provide additional information they consider relevant.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Parkinson's disease (PD)
-
Parkinsonism
-
Parkinson-plus syndromes (e.g. Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), Corticobasal degeneration (CBGD), Dementia with Lewy bodies)
-
Must have online access, an email address, basic computer literacy
-
Must be willing to complete online surveys every 6 months for 5 years
Exclusion Criteria:
-
Inability to read/write English
-
Inability or unwillingness to complete surveys every six (6) months (~90 min)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Bastyr University | Kenmore | Washington | United States | 98028 |
Sponsors and Collaborators
- Bastyr University
Investigators
- Principal Investigator: Laurie K Mischley, ND, PhD, MPH, Bastyr University
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
- Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, Obeso JA, Rascol O, Schapira A, Voon V, Weiner DM, Tison F, Bezard E. Priorities in Parkinson's disease research. Nat Rev Drug Discov. 2011 May;10(5):377-93. doi: 10.1038/nrd3430. Review.
- Positive Deviance Initiative. 2010 [cited 2012 30 Dec 2012]; Available from: http://www.positivedeviance.org/about_pd/index.html
- Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 2010 Nov 15;25(15):2649-53. doi: 10.1002/mds.23429. Review.
- BU-13A-1332